News | June 23, 2021
Shilpa Medicare launches dissolving oral thin films of Paracetamol
Shilpa's Paracetamol oral thin films are patent protected and are first of this kind in the world
Shilpa's Paracetamol oral thin films are patent protected and are first of this kind in the world
The company has posted net profit of Rs.147.78 crores for the 12 months period ended March 31, 2021
The GMP certificate is valid for three years until April 2024.
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
The commercial production in the SML was started in November 1989.
Raichur site is the group’s largest API facility and part of a wider network of seven sites
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis
This is used to treat central diabetes insipidus and bedwetting
Subscribe To Our Newsletter & Stay Updated
